Alpha-Synuclein Produces Early Behavioral Alterations via Striatal Cholinergic Synaptic Dysfunction by Interacting With GluN2D N-Methyl-D-Aspartate Receptor Subunit

Biological Psychiatry

Volumn 79, Issue 5, 2016, Pages 402-414

  Tozzi, Alessandro ^a,b   de Iure, Antonio ^a   Bagetta, Vincenza ^b   Tantucci, Michela ^a   Durante, Valentina ^a   Quiroga Varela, Ana ^a   Costa, Cinzia ^a   Di Filippo, Massimiliano ^a   Ghiglieri, Veronica ^a,b   Latagliata, Emanuele Claudio ^b,c   Wegrzynowicz, Michal ^d   Decressac, Mickael ^e   Giampà, Carmela ^b   Dalley, Jeffrey W ^f   Xia, Jing ^f   Gardoni, Fabrizio ^g   Mellone, Manuela ^g   El Agnaf, Omar Mukhtar ^h   Ardah, Mustafa Taleb ^h   Puglisi Allegra, Stefano ^b,c   Björklund, Anders ^e   Spillantini, Maria Grazia ^d   Picconi, Barbara ^b   Calabresi, Paolo ^a,b   more..

^a UNIVERSITY OF PERUGIA   (Italy)

^b Institutes for Research Hospitalization and Health Care   (United States)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^e LUND UNIVERSITY   (Sweden)

^f UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^g UNIVERSITY OF MILAN   (Italy)

^h UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

Author keywords

Animal models; Cholinergic interneurons; Dopamine; Long term potentiation; Parkinson's disease; Striatum

Indexed keywords

ALPHA SYNUCLEIN; DOPAMINE; GLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PARVOVIRUS VECTOR; NR2D NMDA RECEPTOR; RECOMBINANT PROTEIN; SNCA PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHOLINERGIC INTERNEURON; CHOLINERGIC SYSTEM; COGNITIVE DEFECT; CONTROLLED STUDY; CORPUS STRIATUM; EX VIVO STUDY; EXCITATORY POSTSYNAPTIC POTENTIAL; GENE OVEREXPRESSION; IN VITRO STUDY; INTERNEURON; LONG TERM POTENTIATION; MALE; MOTOR DYSFUNCTION; MOUSE; NERVE CELL PLASTICITY; NONHUMAN; PARKINSON DISEASE; POSTSYNAPTIC DENSITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SPINY PROJECTION NEURON; SYNAPTIC TRANSMISSION; ANIMAL; CHOLINERGIC NERVE CELL; DEPENDOPARVOVIRUS; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; HUMAN; NEOSTRIATUM; PHYSIOLOGY; SPRAGUE DAWLEY RAT; TRANSGENIC ANIMAL; TRANSGENIC MOUSE;

ALPHA-SYNUCLEIN; ANIMALS; ANIMALS, GENETICALLY MODIFIED; CHOLINERGIC NEURONS; DEPENDOVIRUS; DISEASE MODELS, ANIMAL; DOPAMINE; FEMALE; HUMANS; LONG-TERM POTENTIATION; MALE; MICE; MICE, TRANSGENIC; NEOSTRIATUM; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RECOMBINANT PROTEINS; SYNAPTIC TRANSMISSION;

EID: 84942038566     PISSN: 00063223     EISSN: 18732402     Source Type: Journal    
DOI: 10.1016/j.biopsych.2015.08.013     Document Type: Article

References (53)

1. 1 Barnes, T.D., Kubota, Y., Hu, D., Jin, D.Z., Graybiel, A.M., Activity of striatal neurons reflects dynamic encoding and recoding of procedural memories. Nature 437 (2005), 1158–1161.
2. 2 Jin, X., Costa, R.M., Start/stop signals emerge in nigrostriatal circuits during sequence learning. Nature 466 (2010), 457–462.
3. 3 Obeso, J.A., Rodriguez-Oroz, M.C., Rodriguez, M., Lanciego, J.L., Artieda, J., Gonzalo, N., Olanow, C.W., Pathophysiology of the basal ganglia in Parkinson's disease. Trends Neurosci 23 (2000), S8–S19.
4. 4 Calabresi, P., Picconi, B., Tozzi, A., Di Filippo, M., Dopamine-mediated regulation of corticostriatal synaptic plasticity. Trends Neurosci 30 (2007), 211–219.
5. 5 Gerfen, C.R., Surmeier, D.J., Modulation of striatal projection systems by dopamine. Annu Rev Neurosci 34 (2011), 441–466.
6. 6 Calabresi, P., Centonze, D., Gubellini, P., Pisani, A., Bernardi, G., Acetylcholine-mediated modulation of striatal function. Trends Neurosci 23 (2000), 120–126.
7. 7 Pisani, A., Bernardi, G., Ding, J., Surmeier, D.J., Re-emergence of striatal cholinergic interneurons in movement disorders. Trends Neurosci 30 (2007), 545–553.
8. 8 Ding, J.B., Guzman, J.N., Peterson, J.D., Goldberg, J.A., Surmeier, D.J., Thalamic gating of corticostriatal signaling by cholinergic interneurons. Neuron 67 (2010), 294–307.
9. 9 Threlfell, S., Lalic, T., Platt, N.J., Jennings, K.A., Deisseroth, K., Cragg, S.J., Striatal dopamine release is triggered by synchronized activity in cholinergic interneurons. Neuron 75 (2012), 58–64.
10. 10 Lapper, S.R., Bolam, J.P., Input from the frontal cortex and the parafascicular nucleus to cholinergic interneurons in the dorsal striatum of the rat. Neuroscience 51 (1992), 533–545.
11. 11 Cragg, S.J., Meaningful silences: How dopamine listens to the ACh pause. Trends Neurosci 29 (2006), 125–131.
12. 12 Polymeropoulos, M.H., Lavedan, C., Leroy, E., Ide, S.E., Dehejia, A., Dutra, A., et al. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276 (1997), 2045–2047.
13. 13 Spillantini, M.G., Schmidt, M.L., Lee, V.M., Trojanowski, J.Q., Jakes, R., Goedert, M., Alpha-synuclein in Lewy bodies. Nature 388 (1997), 839–840.
14. 14 Vekrellis, K., Xilouri, M., Emmanouilidou, E., Rideout, H.J., Stefanis, L., Pathological roles of alpha-synuclein in neurological disorders. Lancet Neurol 10 (2011), 1015–1025.
15. 15 Janezic, S., Threlfell, S., Dodson, P.D., Dowie, M.J., Taylor, T.N., Potgieter, D., et al. Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc Natl Acad Sci U S A 110 (2013), E4016–E4025.
16. 16 Garcia-Reitbock, P., Anichtchik, O., Bellucci, A., Iovino, M., Ballini, C., Fineberg, E., et al. SNARE protein redistribution and synaptic failure in a transgenic mouse model of Parkinson's disease. Brain 133 (2010), 2032–2044.
17. 17 Tofaris, G.K., Garcia Reitbock, P., Humby, T., Lambourne, S.L., O'Connell, M., Ghetti, B., et al. Pathological changes in dopaminergic nerve cells of the substantia nigra and olfactory bulb in mice transgenic for truncated human alpha-synuclein(1-120): Implications for Lewy body disorders. J Neurosci 26 (2006), 3942–3950.
18. 18 Decressac, M., Mattsson, B., Bjorklund, A., Comparison of the behavioural and histological characteristics of the 6-OHDA and alpha-synuclein rat models of Parkinson's disease. Exp Neurol 235 (2012), 306–315.
19. 19 Picconi, B., Centonze, D., Hakansson, K., Bernardi, G., Greengard, P., Fisone, G., et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 6 (2003), 501–506.
20. 20 Puglisi-Allegra, S., Cabib, S., Pascucci, T., Ventura, R., Cali, F., Romano, V., Dramatic brain aminergic deficit in a genetic mouse model of phenylketonuria. Neuroreport 11 (2000), 1361–1364.
21. 21 Gardoni, F., Caputi, A., Cimino, M., Pastorino, L., Cattabeni, F., Di Luca, M., Calcium/calmodulin-dependent protein kinase II is associated with NR2A/B subunits of NMDA receptor in postsynaptic densities. J Neurochem 71 (1998), 1733–1741.
22. 22 Bagetta, V., Picconi, B., Marinucci, S., Sgobio, C., Pendolino, V., Ghiglieri, V., et al. Dopamine-dependent long-term depression is expressed in striatal spiny neurons of both direct and indirect pathways: Implications for Parkinson's disease. J Neurosci 31 (2011), 12513–12522.
23. 23 White, N.M., McDonald, R.J., Multiple parallel memory systems in the brain of the rat. Neurobiol Learn Mem 77 (2002), 125–184.
24. 24 Ardah, M.T., Paleologou, K.E., Lv, G., Abul Khair, S.B., Kazim, A.S., Minhas, S.T., et al. Structure activity relationship of phenolic acid inhibitors of alpha-synuclein fibril formation and toxicity. Front Aging Neurosci, 6, 2014, 197.
25. 25 Kawaguchi, Y., Wilson, C.J., Augood, S.J., Emson, P.C., Striatal interneurones: Chemical, physiological and morphological characterization. Trends Neurosci 18 (1995), 527–535.
26. 26 Tozzi, A., de Iure, A., Di Filippo, M., Tantucci, M., Costa, C., Borsini, F., et al. The distinct role of medium spiny neurons and cholinergic interneurons in the D(2)/A(2)A receptor interaction in the striatum: Implications for Parkinson's disease. J Neurosci 31 (2011), 1850–1862.
27. 27 Berlanga, M.L., Simpson, T.K., Alcantara, A.A., Dopamine D5 receptor localization on cholinergic neurons of the rat forebrain and diencephalon: A potential neuroanatomical substrate involved in mediating dopaminergic influences on acetylcholine release. J Comp Neurol 492 (2005), 34–49.
28. 28 Fadok, J.P., Dickerson, T.M., Palmiter, R.D., Dopamine is necessary for cue-dependent fear conditioning. J Neurosci 29 (2009), 11089–11097.
29. 29 Paille, V., Picconi, B., Bagetta, V., Ghiglieri, V., Sgobio, C., Di Filippo, M., et al. Distinct levels of dopamine denervation differentially alter striatal synaptic plasticity and NMDA receptor subunit composition. J Neurosci 30 (2010), 14182–14193.
30. 30 Centonze, D., Gubellini, P., Picconi, B., Calabresi, P., Giacomini, P., Bernardi, G., Unilateral dopamine denervation blocks corticostriatal LTP. J Neurophysiol 82 (1999), 3575–3579.
31. 31 Landwehrmeyer, G.B., Standaert, D.G., Testa, C.M., Penney, J.B. Jr, Young, A.B., NMDA receptor subunit mRNA expression by projection neurons and interneurons in rat striatum. J Neurosci 15 (1995), 5297–5307.
32. 32 Bloomfield, C., O'Donnell, P., French, S.J., Totterdell, S., Cholinergic neurons of the adult rat striatum are immunoreactive for glutamatergic N-methyl-d-aspartate 2D but not N-methyl-d-aspartate 2C receptor subunits. Neuroscience 150 (2007), 639–646.
33. 33 Standaert, D.G., Testa, C.M., Rudolf, G.D., Hollingsworth, Z.R., Inhibition of N-methyl-D-aspartate glutamate receptor subunit expression by antisense oligonucleotides reveals their role in striatal motor regulation. J Pharmacol Exp Ther 276 (1996), 342–352.
34. 34 Suzuki, T., Miura, M., Nishimura, K., Aosaki, T., Dopamine-dependent synaptic plasticity in the striatal cholinergic interneurons. J Neurosci 21 (2001), 6492–6501.
35. 35 Feng, Z.J., Zhang, X., Chergui, K., Allosteric modulation of NMDA receptors alters neurotransmission in the striatum of a mouse model of Parkinson's disease. Exp Neurol 255 (2014), 154–160.
36. 36 Zhang, X., Feng, Z.J., Chergui, K., Allosteric modulation of GluN2C/GluN2D-containing NMDA receptors bidirectionally modulates dopamine release: Implication for Parkinson's disease. Br J Pharmacol 171 (2014), 3938–3945.
37. 37 Zhang, X., Feng, Z.J., Chergui, K., GluN2D-containing NMDA receptors inhibit neurotransmission in the mouse striatum through a cholinergic mechanism: Implication for Parkinson's disease. J Neurochem 129 (2014), 581–590.
38. 38 Diogenes, M.J., Dias, R.B., Rombo, D.M., Vicente Miranda, H., Maiolino, F., Guerreiro, P., et al. Extracellular alpha-synuclein oligomers modulate synaptic transmission and impair LTP via NMDA-receptor activation. J Neurosci 32 (2012), 11750–11762.
39. 39 Overk, C.R., Masliah, E., Pathogenesis of synaptic degeneration in Alzheimer's disease and Lewy body disease. Biochem Pharmacol 88 (2014), 508–516.
40. 40 Vastagh, C., Gardoni, F., Bagetta, V., Stanic, J., Zianni, E., Giampa, C., et al. N-methyl-D-aspartate (NMDA) receptor composition modulates dendritic spine morphology in striatal medium spiny neurons. J Biol Chem 287 (2012), 18103–18114.
41. 41 Jankovic, J., Levodopa strengths and weaknesses. Neurology 58 (2002), S19–S32.
42. 42 Cools, R., Barker, R.A., Sahakian, B.J., Robbins, T.W., Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 11 (2001), 1136–1143.
43. 43 Doig, N.M., Magill, P.J., Apicella, P., Bolam, J.P., Sharott, A., Cortical and thalamic excitation mediate the multiphasic responses of striatal cholinergic interneurons to motivationally salient stimuli. J Neurosci 34 (2014), 3101–3117.
44. 44 Lopes da Fonseca, T., Villar-Pique, A., Outeiro, T.F., The interplay between alpha-synuclein clearance and spreading. Biomolecules 5 (2015), 435–471.
45. 45 Chuhma, N., Mingote, S., Moore, H., Rayport, S., Dopamine neurons control striatal cholinergic neurons via regionally heterogeneous dopamine and glutamate signaling. Neuron 81 (2014), 901–912.
46. 46 Straub, C., Tritsch, N.X., Hagan, N.A., Gu, C., Sabatini, B.L., Multiphasic modulation of cholinergic interneurons by nigrostriatal afferents. J Neurosci 34 (2014), 8557–8569.
47. 47 Wieland, S., Du, D., Oswald, M.J., Parlato, R., Kohr, G., Kelsch, W., Phasic dopaminergic activity exerts fast control of cholinergic interneuron firing via sequential NMDA, D2, and D1 receptor activation. J Neurosci 34 (2014), 11549–11559.
48. 48 Voon, V., Mehta, A.R., Hallett, M., Impulse control disorders in Parkinson's disease: Recent advances. Curr Opin Neurol 24 (2011), 324–330.
49. 49 Voon, V., Sohr, M., Lang, A.E., Potenza, M.N., Siderowf, A.D., Whetteckey, J., et al. Impulse control disorders in Parkinson disease: A multicenter case-control study. Ann Neurol 69 (2011), 986–996.
50. 50 Cachope, R., Mateo, Y., Mathur, B.N., Irving, J., Wang, H.L., Morales, M., et al. Selective activation of cholinergic interneurons enhances accumbal phasic dopamine release: Setting the tone for reward processing. Cell Rep 2 (2012), 33–41.
51. 51 Calabresi, P., Picconi, B., Parnetti, L., Di Filippo, M., A convergent model for cognitive dysfunctions in Parkinson's disease: The critical dopamine-acetylcholine synaptic balance. Lancet Neurol 5 (2006), 974–983.
52. 52 Witten, I.B., Lin, S.C., Brodsky, M., Prakash, R., Diester, I., Anikeeva, P., et al. Cholinergic interneurons control local circuit activity and cocaine conditioning. Science 330 (2010), 1677–1681.
53. 53 Calabresi, P., Picconi, B., Tozzi, A., Ghiglieri, V., Di Filippo, M., Direct and indirect pathways of basal ganglia: A critical reappraisal. Nat Neurosci 17 (2014), 1022–1030.